myeloproliferative neoplasms (MPN) | Page 5 | Aplastic Anemia & MDS International Foundation

myeloproliferative neoplasms (MPN)

Trial of the Combination of Bortezomib and Clofarabine in Adults With Relapsed Solid Tumors

Background:

- Researchers want to develop better ways to treat cancer. In this study, they will give people with cancer two drugs. These drugs have been used on their own to treat some blood cell cancers.

Objectives:

- To test the safety and efficacy of the drug combination of bortezomib and clofarabine.

Eligibility:

- Adults age 18 and over with advanced cancer that has progressed after receiving standard treatment or that has no effective therapy.

Design:

Hemant Murthy, MD

Murthy, Hemant
Physician
Mayo Clinic - Jacksonville

Hemant S. Murthy M.D., is a Hematology/Oncology physician, with specialty interest in BMT/CAR-T and acute leukemia practice. Dr. Murthy previously served as Assistant Professor of Medicine at the University of Florida College of Medicine in Gainesville, Florida. Prior to joining UF Health, Dr. Murthy was a transplant and cellular immunotherapy fellow at Moffitt Cancer Center.

Mark Litzow, MD

Litzow, Mark
Professor
Mayo Clinic - Rochester

Dr. Litzow is Professor of Medicine in the Division of Hematology at Mayo Clinic in Rochester, Minnesota. He was the Director of the BMT Program at Mayo from 1992 to 2008 and continues to remain active in the BMT program. He was the Director of the Myeloid Disease Oriented Group in the Division of Hematology from 2002 to 2016. He was appointed chair of the Leukemia Committee of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network (ECOG-ACRIN) in September 2013 after having served as co-chair of the committee since 2001.